These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30670830)

  • 1. Approvals in 2018: a histology-agnostic new molecular entity, novel end points and real-time review.
    Blumenthal GM; Pazdur R
    Nat Rev Clin Oncol; 2019 Mar; 16(3):139-141. PubMed ID: 30670830
    [No Abstract]   [Full Text] [Related]  

  • 2. Inappropriate use of progression-free survival in cancer drug approvals.
    Naci H; Davis C
    BMJ; 2020 Mar; 368():m770. PubMed ID: 32156802
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019.
    Chen EY; Haslam A; Prasad V
    JAMA Intern Med; 2020 Jun; 180(6):912-914. PubMed ID: 32338703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. US Food and Drug Administration approves first cancer treatment for any solid tumors with specific biomarker.
    Cancer; 2017 Oct; 123(19):3652-3653. PubMed ID: 28940329
    [No Abstract]   [Full Text] [Related]  

  • 5. Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.
    Seligson ND; Knepper TC; Ragg S; Walko CM
    Clin Pharmacol Ther; 2021 Feb; 109(2):334-342. PubMed ID: 32535906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug approvals 2011: focus on companion diagnostics.
    Goozner M
    J Natl Cancer Inst; 2012 Jan; 104(2):84-6. PubMed ID: 22215850
    [No Abstract]   [Full Text] [Related]  

  • 7. Approvals in 2019: international review and a new agnostic molecular entity.
    Singh H; Blumenthal G; Pazdur R
    Nat Rev Clin Oncol; 2020 Mar; 17(3):130-131. PubMed ID: 32047277
    [No Abstract]   [Full Text] [Related]  

  • 8. Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals.
    Kim C; Prasad V
    JAMA Intern Med; 2015 Dec; 175(12):1992-4. PubMed ID: 26502403
    [No Abstract]   [Full Text] [Related]  

  • 9. Assessing tumor-related signs and symptoms to support cancer drug approval.
    Williams G; Pazdur R; Temple R
    J Biopharm Stat; 2004 Feb; 14(1):5-21. PubMed ID: 15027497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
    Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
    Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response Rate as an Approval End Point in Oncology: Back to the Future.
    Blumenthal GM; Pazdur R
    JAMA Oncol; 2016 Jun; 2(6):780-1. PubMed ID: 26913938
    [No Abstract]   [Full Text] [Related]  

  • 12. Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?
    Hierro C; Matos I; Martin-Liberal J; Ochoa de Olza M; Garralda E
    Clin Cancer Res; 2019 Jun; 25(11):3210-3219. PubMed ID: 30670489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Does oncology change its paradigm? The challenge of agnostic approval of new therapies.].
    Martini N
    Recenti Prog Med; 2018 Jun; 109(6):317-318. PubMed ID: 29968857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. End points and United States Food and Drug Administration approval of oncology drugs.
    Johnson JR; Williams G; Pazdur R
    J Clin Oncol; 2003 Apr; 21(7):1404-11. PubMed ID: 12663734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Indications and Approvals for Anticancer Drugs.
    Aschenbrenner DS
    Am J Nurs; 2021 Dec; 121(12):16-17. PubMed ID: 34792500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant trials could speed up drug approvals.
    Peres J
    J Natl Cancer Inst; 2014 Mar; 106(3):dju072. PubMed ID: 24610911
    [No Abstract]   [Full Text] [Related]  

  • 17. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials.
    Chen EY; Joshi SK; Tran A; Prasad V
    JAMA Intern Med; 2019 May; 179(5):642-647. PubMed ID: 30933235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in the approval of cancer therapies by the FDA in the twenty-first century.
    Scott EC; Baines AC; Gong Y; Moore R; Pamuk GE; Saber H; Subedee A; Thompson MD; Xiao W; Pazdur R; Rao VA; Schneider J; Beaver JA
    Nat Rev Drug Discov; 2023 Aug; 22(8):625-640. PubMed ID: 37344568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trial offers early test case for personalized medicine.
    Garber K
    J Natl Cancer Inst; 2009 Feb; 101(3):136-8. PubMed ID: 19176464
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.